source
- Novartis' del-desiran misses primary goal in late-stage myotonic dystrophy trialNovartis announced that its experimental RNA drug del-desiran did not achieve the primary endpoint in a late-stage study of myotonic dystrophy type 1, a rare muscle‑weakening disease. The trial me…
- FDA approves AstraZeneca's oral SERD Etcamah for HR+/HER2-negative advanced breast cancerFDA granted approval to AstraZeneca's camizestrant, marketed as Etcamah, an oral selective estrogen receptor degrader (SERD) for a specific subset of advanced breast cancer patients. The indicatio…